Delivery Order SPE2DB22D2214-SPE2DB25FS6MJ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for Benlysta 200 mg/ml auto-injector with a ceiling value of $9,248.01. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under the company's existing contract vehicle. The order is scheduled for completion by September 24, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania location. Benlysta (belimumab) is a biologic...
- The Defense Logistics Agency awarded a $9,248.01 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on July 30, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a $3,082.67 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This competitive award, utilizing firm fixed pricing with no set-aside designation, is scheduled for completion by August 14, 2025, with fulfillment performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic medication used primarily in the treatment of systemic lupus...
- The Defense Logistics Agency awarded a $6,165.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on September 9, 2025, with completion targeted for September 30, 2025. This non-set-aside competitive award is part of AmerisourceBergen's broader pharmaceutical supply relationship with the federal government and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Benlysta 200 mg/ml auto-injector units. This competitively awarded, non-set-aside contract has a ceiling value of $12,330.68 and is classified as a firm fixed price delivery order with an ultimate completion date of September 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Benlysta is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,165.34 for Benlysta 200 mg/ml auto-injectors on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Benlysta (belimumab) is a biologic medication used to treat systemic lupus erythematosus and other...
- The Defense Logistics Agency awarded a delivery order valued at $9,248.01 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on September 8, 2025, with an ultimate completion date of September 29, 2025. This is a firm fixed price delivery order with no set-aside designation, placing performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively awarded transaction under AmerisourceBergen's broader pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/mL auto-injector on August 19, 2025. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 10, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified vendors in the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector pharmaceutical products with a ceiling value of $6,165.34 under a firm fixed-price contract. This non-set-aside delivery order, issued on August 1, 2025, is scheduled for ultimate completion by August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta is a biologic immunosuppressant used to treat systemic...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for the supply of Benlysta 200 mg/ml auto-injector on August 5, 2025, with completion targeted for August 26, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement utilizing the company's existing Indefinite Delivery Contract vehicle. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, supporting federal...
- SPE2DB22D2214Indefinite Delivery Contract
- SPE2DB22D2214-SPE2DB25FS6MJDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Benlysta 200 mg/mL auto-injector with a ceiling value of $6,165.34. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement. The contract is set to conclude by September 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Benlysta is a targeted biologic therapy used in the treatment of systemic lupus erythematosus, representing a specialized pharmaceutical product within the federal medical supply chain. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen maintains an extensive portfolio of medical product deliveries across multiple therapeutic domains to support military and veteran healthcare systems. The parent IDC enables the company to supply brand-name and generic medications, vaccines, and specialized medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 9/9/25 |